electroCore, Inc. advances gammaCore in PTSD with first patient enrollment. Read why this 2026 medtech catalyst could matter more than it appears.
Aesyra’s AesyBite Active reduced sleep bruxism by over 60% in trial. Find out what this could mean for digital therapeutics and FDA approval in 2026.
MRM Health's MH002 enters phase 2b for ulcerative colitis. Can this live biotherapeutic redefine immune-sparing treatment in IBD? Find out what’s at stake.
Johnson & Johnson (J&J) announced that its investigational candidate JNJ-95475939 (JNJ-5939) failed to meet prespecified efficacy criteria in the DUPLEX-AD Phase 2b trial for moderate to severe atopic dermatitis. Following an interim analysis, the study was terminated early. Despite showing a favorable tolerability profile, the molecule did not demonstrate sufficient clinical efficacy to warrant continuation.
Amgen has received approval from the United States Food and Drug Administration for Uplizna (inebilizumab-cdon) to treat adults with generalized myasthenia gravis who are anti-acetylcholine receptor or anti-muscle specific tyrosine kinase antibody positive. The greenlight makes Uplizna the first and only CD19-targeted B cell therapy approved for this patient population, introducing a twice-yearly dosing regimen